

Leilei Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3347211/publications.pdf>

Version: 2024-02-01

67
papers

3,846
citations

117625

34
h-index

128289

60
g-index

74
all docs

74
docs citations

74
times ranked

5686
citing authors

#	ARTICLE	IF	CITATIONS
1	p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain). <i>Oncogene</i> , 2022, 41, 2106-2121.	5.9	3
2	ADARs act as potent regulators of circular transcriptome in cancer. <i>Nature Communications</i> , 2022, 13, 1508.	12.8	29
3	Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer. <i>Nature Communications</i> , 2022, 13, 1793.	12.8	9
4	Pan-cancer pervasive upregulation of 3' UTR splicing drives tumorigenesis. <i>Nature Cell Biology</i> , 2022, 24, 928-939.	10.3	18
5	RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2021, 74, 135-147.	3.7	41
6	MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma. <i>Oncogene</i> , 2021, 40, 1851-1867.	5.9	11
7	RNA Editing Signature to Guide Gastric Cancer Chemotherapy. <i>Cancer Research</i> , 2021, 81, 2788-2798.	0.9	9
8	Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer. <i>Molecular Therapy</i> , 2021, 29, 3258-3273.	8.2	13
9	The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment. <i>Current Medicinal Chemistry</i> , 2021, 28, 5110-5136.	2.4	5
10	Profiling of 3D Genome Organization in Nasopharyngeal Cancer Needle Biopsy Patient Samples by a Modified Hi-C Approach. <i>Frontiers in Genetics</i> , 2021, 12, 673530.	2.3	4
11	Pseudogene-mediated DNA demethylation leads to oncogene activation. <i>Science Advances</i> , 2021, 7, eabg1695.	10.3	12
12	CSI NGS Portal: An Online Platform for Automated NGS Data Analysis and Sharing. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3828.	4.1	19
13	Suppression of adenosine-to-inosine (A-to-I) RNA editome by death associated protein 3 (DAP3) promotes cancer progression. <i>Science Advances</i> , 2020, 6, eaba5136.	10.3	29
14	Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development. <i>Nature Communications</i> , 2020, 11, 799.	12.8	69
15	CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer. <i>Theranostics</i> , 2019, 9, 6157-6174.	10.0	32
16	Systematic evaluation and optimization of the experimental steps in RNA G-quadruplex structure sequencing. <i>Scientific Reports</i> , 2019, 9, 8091.	3.3	13
17	Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	109
18	Overexpression of MUC13, a Poor Prognostic Predictor, Promotes Cell Growth by Activating Wnt Signaling in Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2018, 188, 378-391.	3.8	34

#	ARTICLE	IF	CITATIONS
19	ApoA-1 accelerates regeneration of small-for-size fatty liver graft after transplantation. <i>Life Sciences</i> , 2018, 215, 128-135.	4.3	12
20	Bidirectional regulation of adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase 9 (DHX9) in cancer. <i>Nucleic Acids Research</i> , 2018, 46, 7953-7969.	14.5	41
21	Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. <i>Blood</i> , 2018, 132, 1304-1317.	1.4	67
22	AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	91
23	An RNA editing/dsRNA binding-independent gene regulatory mechanism of ADARs and its clinical implication in cancer. <i>Nucleic Acids Research</i> , 2017, 45, 10436-10451.	14.5	50
24	AKR7A3 suppresses tumorigenicity and chemoresistance in hepatocellular carcinoma through attenuation of ERK, c-Jun and NF- κ B signaling pathways. <i>Oncotarget</i> , 2017, 8, 83469-83479.	1.8	24
25	ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. <i>Gastroenterology</i> , 2016, 151, 637-650.e10.	1.3	127
26	CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors. <i>Hepatology</i> , 2016, 63, 1544-1559.	7.3	32
27	Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. <i>Gastroenterology</i> , 2015, 149, 1068-1081.e5.	1.3	50
28	Regulatory factors governing adenosine-to-inosine (A-to-I) RNA editing. <i>Bioscience Reports</i> , 2015, 35, .	2.4	11
29	Overexpression of N-terminal kinase like gene promotes tumorigenicity of hepatocellular carcinoma by regulating cell cycle progression and cell motility. <i>Oncotarget</i> , 2015, 6, 1618-1630.	1.8	10
30	ADAR1: a promising new biomarker for esophageal squamous cell carcinoma?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 865-868.	2.4	13
31	Adenosine-to-Inosine RNA Editing Mediated by ADARs in Esophageal Squamous Cell Carcinoma. <i>Cancer Research</i> , 2014, 74, 840-851.	0.9	152
32	A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. <i>Gut</i> , 2014, 63, 832-843.	12.1	187
33	RNA Editome Imbalance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2014, 74, 1301-1306.	0.9	47
34	Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3 β /Snail signaling. <i>Hepatology</i> , 2014, 59, 531-543.	7.3	110
35	Allele-Specific Imbalance of Oxidative Stress-Induced Growth Inhibitor 1 Associates With Progression of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2014, 146, 1084-1096.e5.	1.3	33
36	Hepatocellular carcinoma: Transcriptome diversity regulated by RNA editing. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1843-1848.	2.8	17

#	ARTICLE	IF	CITATIONS
37	Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2013, 436, 711-718.	2.1	61
38	SPOCK1 Is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice. <i>Gastroenterology</i> , 2013, 144, 179-191.e4.	1.3	94
39	Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. <i>Nature Medicine</i> , 2013, 19, 209-216.	30.7	421
40	Characterization of <i>CACNA2D3</i> as a putative tumor suppressor gene in the development and progression of nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2013, 133, 2284-2295.	5.1	42
41	Downregulation of the Novel Tumor Suppressor DIRAS1 Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma. <i>Cancer Research</i> , 2013, 73, 2298-2309.	0.9	50
42	Establishment and characterization of human non-small cell lung cancer cell lines. <i>Molecular Medicine Reports</i> , 2012, 5, 114-7.	2.4	9
43	SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma. <i>Carcinogenesis</i> , 2012, 33, 1581-1588.	2.8	13
44	Role of Translationally Controlled Tumor Protein in Cancer Progression. <i>Biochemistry Research International</i> , 2012, 2012, 1-5.	3.3	31
45	MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. <i>Gut</i> , 2012, 61, 33-42.	12.1	223
46	Interleukin 23 Promotes Hepatocellular Carcinoma Metastasis via NF-Kappa B Induced Matrix Metalloproteinase 9 Expression. <i>PLoS ONE</i> , 2012, 7, e46264.	2.5	68
47	Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma. <i>Hepatology</i> , 2012, 55, 1754-1765.	7.3	41
48	Translationally controlled tumor protein induces mitotic defects and chromosome missegregation in hepatocellular carcinoma development. <i>Hepatology</i> , 2012, 55, 491-505.	7.3	71
49	Chemically-Induced Cancers Do Not Originate from Bone Marrow-Derived Cells. <i>PLoS ONE</i> , 2012, 7, e30493.	2.5	3
50	<i>Spatholobus suberectus</i> inhibits cancer cell growth by inducing apoptosis and arresting cell cycle at G2/M checkpoint. <i>Journal of Ethnopharmacology</i> , 2011, 133, 751-758.	4.1	45
51	Interleukin 17A Promotes Hepatocellular Carcinoma Metastasis via NF-κB Induced Matrix Metalloproteinases 2 and 9 Expression. <i>PLoS ONE</i> , 2011, 6, e21816.	2.5	168
52	Overexpression of Cathepsin Z Contributes to Tumor Metastasis by Inducing Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e24967.	2.5	79
53	Overexpression of eIF-5A2 in mice causes accelerated organismal aging by increasing chromosome instability. <i>BMC Cancer</i> , 2011, 11, 199.	2.6	17
54	Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2011, 11, 86.	2.6	30

#	ARTICLE	IF	CITATIONS
55	Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion. <i>Gut</i> , 2011, 60, 534-543.	12.1	46
56	Downregulation of RBMS3 Is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma. <i>Cancer Research</i> , 2011, 71, 6106-6115.	0.9	47
57	Characterization of Tumor-Suppressive Function of SOX6 in Human Esophageal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 46-55.	7.0	73
58	Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. <i>Hepatology</i> , 2010, 51, 1255-1263.	7.3	138
59	Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma. <i>Hepatology</i> , 2010, 51, 1624-1634.	7.3	48
60	Characterization of a Novel Mechanism of Genomic Instability Involving the SEI1/SET/NM23H1 Pathway in Esophageal Cancers. <i>Cancer Research</i> , 2010, 70, 5695-5705.	0.9	31
61	Characterization of a Candidate Tumor Suppressor Gene Uroplakin 1A in Esophageal Squamous Cell Carcinoma. <i>Cancer Research</i> , 2010, 70, 8832-8841.	0.9	39
62	Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 1165-1171.	6.1	45
63	CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. <i>Journal of Clinical Investigation</i> , 2010, 120, 1178-1191.	8.2	132
64	Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1L) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival. <i>Hepatology</i> , 2009, 50, 122-129.	7.3	61
65	Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker. <i>Annals of Hematology</i> , 2009, 88, 29-36.	1.8	1
66	Transgenic CHD1L Expression in Mouse Induces Spontaneous Tumors. <i>PLoS ONE</i> , 2009, 4, e6727.	2.5	47
67	Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 503-510.	7.3	128